| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6062493 | Journal of Allergy and Clinical Immunology | 2016 | 13 Pages |
Abstract
This meta-analysis provides high-quality evidence for the efficacy and safety of omalizumab in patients with CSU and for treating these patients with 300Â mg of omalizumab every 4Â weeks.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Zuo-Tao MD, PhD, Chun-Mei M Pharm, Wen-Jun MD, Ling M Pharm, Tomasz MD, Ji-Fu PhD, Marcus MD,